###### Strengths and limitations of this study

-   This is the first systematic review and meta-analysis to assess the effectiveness of complex multiple-risk lifestyle interventions in reducing depressive symptoms by the promotion of healthy habits in the adult population.

-   This study will be conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement for reporting systematic reviews and meta-analyses.

-   The effect size, robustness and quality of evidence of the studies included in this meta-analysis will help to determine whether symptoms of depression can be improved by complex multiple-risk lifestyle interventions based on the acquisition of healthy habits.

-   This study will have the limitations inherent to all systematic reviews and meta-analyses (ie, missing outcome data, methodological flaws and risk of bias of the studies included).

-   Bias, heterogeneity and the small sample of studies could limit the interpretation of results.

Introduction {#s1}
============

Depression affects more than 300 million people worldwide and is the first global cause of disability.[@R1] Some studies have shown that pharmacological and psychological treatments reduce disease burden by less than 30%.[@R2] Many randomised controlled trials (RCTs) and systematic reviews have been conducted to assess the efficacy of different interventions in the prevention of depression, the reduction of new episodes[@R3] or the improvement of depressive symptoms.[@R6]

Recent compelling evidence suggests that depression has a significant lifestyle-driven component.[@R8] It is increasingly accepted that poor sleep, dietary habits, smoking and sedentary habits are important modifiable risk factors for depressive disorders.[@R9] Nowadays, the most prevalent lifestyle risk factors in many countries include tobacco use, physical inactivity and unhealthy diet.[@R13]

In most studies, lifestyle interventions for the prevention of depression are only focused on a specific healthy habit.[@R17] Nevertheless, unhealthy lifestyle factors tend to co-occur; it has been reported that 31%--40% of the population has at least two risk factors.[@R14] Evidence suggests that complex multiple-risk lifestyle interventions provide greater health benefits, reduce costs and optimise the promotion of healthy habits.[@R28]

According to our search, only three systematic reviews and meta-analyses have explored the effect of multifactorial lifestyle interventions on symptoms of depression. One of these studies[@R29] was focused on both single and multifactorial lifestyle interventions promoting healthy diet and physical activity in high-risk or type-2 diabetes patients. The other study[@R30] only evaluated a lifestyle/psychological intervention versus a multi-component intervention based on a combination of lifestyle and psychological interventions in patients with chronic obstructive pulmonary disease. The third study[@R31] assessed the effects of dietary interventions and complex multiple-risk lifestyle interventions. Thus, most studies were focused on dietary and physical activity interventions addressed at a specific population. Some complex interventions combined a psychological intervention with an intervention on a specific lifestyle habit.[@R30]

To the best of our knowledge, no systematic review or meta-analysis has been performed so far to explore the effectiveness of complex multiple-risk lifestyle interventions in reducing depressive symptoms in the adult population.

A systematic review and meta-analysis of RCTs will be conducted. The objective is to assess the effectiveness of complex multiple-risk lifestyle interventions in reducing depressive symptoms in the adult population by the promotion of at least two healthy habits (healthy diet, physical activity and/or smoking cessation). The research question of this study will be: *Are complex multiple-risk lifestyle interventions effective in improving symptoms of depression in the adult population?* This study will help to understand if symptoms of depression improve with the implementation of complex multiple-risk lifestyle interventions promoting the acquisition of healthy habits. The expected results will have multiple implications, since complex multiple-risk lifestyle interventions prevent other non-communicable diseases,[@R32] reduce medical costs[@R33] and improve self-efficacy in patients.[@R34] Furthermore, complex multiple-risk lifestyle interventions respond accurately to clustering of unhealthy lifestyle factors[@R14] and can easily be implemented in different settings.[@R26]

Methods and analysis {#s2}
====================

This protocol was designed in accordance with the 2015 Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols.[@R37] The protocol was registered with the International Register of Systematic Reviews (<http://www.crd.york.ac.uk/>PROSPERO) on 18 September 2018.

Eligibility criteria {#s2a}
--------------------

The rationale for the inclusion and exclusion criteria (using PICOS acronym[@R38]) was to select RCTs (S) assessing the effectiveness of complex multiple-risk lifestyle interventions (I)---as compared with usual care (ie, staying in the waiting list, no intervention or joining an attention control group \[C\])---in promoting healthy behaviours to reduce symptoms of depression (O) in the adult population (P). [Table 1](#T1){ref-type="table"} presents the inclusion and exclusion criteria.

###### 

Inclusion and exclusion criteria

  Criteria       Inclusion criteria                                                                                                                                         Exclusion criteria
  -------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Population     Adults over 18 years of age.                                                                                                                               Studies which target population are patients meeting the diagnostic criteria for clinical depression.
  Intervention   Complex multiple-risk lifestyle interventions addressing at least two of the following factors: healthy diet, physical activity and smoking cessation\*.   Any other intervention that was not a complex multiple-risk lifestyle intervention.
  Comparator     Usual care, waiting list, non- intervention or attention controls (active control or placebo)                                                              Any other type of comparison or intervention.
  Outcome        Reduction of symptoms of depression.                                                                                                                       Interventions which effects on depression or other diseases are not reported separately (or which effective measures are not provided separately).
  Study design   Randomised controlled trials, randomised clinical trials or clinical trials                                                                                Prospective cohort, retrospective cohort, cross-sectional, case-control, systematic reviews and meta-analysis, protocols, clinical case, editors' letters, qualitative studies and observational studies
  Language       All languages                                                                                                                                              None
  Setting        All settings                                                                                                                                               None

\*Interventions or programmes addressing at least two of the following factors: healthy diet, physical activity and/or smoking cessation. Healthy diet: Mediterranean diet, Dietary Approaches to Stop Hypertension diet, Japanese diet, any diet with a goal of five pieces of fruit and vegetables per day and any diet where saturated fats account for less than 10% of the total daily energy intake. Physical activity: At least 150 minutes of moderate-intensity aerobic physical activity throughout the week, or at least 75 minutes of vigorous-intensity aerobic physical activity throughout the week, or an equivalent combination of moderate-intensity and vigorous-intensity activities. Smoking cessation: Any smoking cessation intervention with a self-reported and/or biochemically validated abstinence outcome measure of continuous abstinence, and/or prolonged abstinence, and/or point prevalence; and studies where treatment effect size is reported based either on the absolute percentage difference between abstinent subjects and smokers or the magnitude of the difference between active and control conditions.

Study design {#s2b}
------------

Only randomised control and clinical trials will be included, since according to the 'hierarchy of evidence', these designs provide the best evidence for healthcare interventions.[@R39] In relation to cluster randomised control/clinical trials, we will only include those with at least two clusters per intervention and per control group, with analysis of effectiveness was adjusted for the clustering effect. Observational studies, non-RCTs and before--after studies will be excluded. Concerning more than two-arm interventions, we will only include the arms that meet our inclusion criteria.

Participants, setting, time frame and language {#s2c}
----------------------------------------------

We will consider the entire adult population, with no restrictions in terms of disease or health status (ie, healthy people and patients with chronic diseases, among others). Participants must be 18 years or older. No other sociodemographic restrictions will be imposed. All settings will be considered and no time frame or language restrictions will be applied to the literature search. In purely preventive intervention studies, baseline depression must have been discarded using a standardised diagnostic tool or a threshold in a validated scale. In relation to inclusion criteria, as it is unlikely that baseline depression was assessed in RCTs to exclude depressive patients, it will only be required that baseline symptoms of depression were assessed. Baseline depression scores will be considered to clearly distinguish between different types of prevention interventions. Studies which target population includes only patients meeting the diagnostic criteria for clinical depression will be excluded, as these are considered treatment rather than preventive interventions.

Type of intervention {#s2d}
--------------------

We will include complex multiple-risk lifestyle interventions, defined as interventions or programmes promoting the acquisition of at least two of the following healthy habits: healthy diet, physical activity and/or smoking cessation. Quantitative and qualitative approaches will be used for evaluating healthy diet interventions. Healthy diets include the Mediterranean diet,[@R40] the Dietary Approaches to Stop Hypertension diet,[@R42] the Japanese diet,[@R44] any diet with a target of five pieces of fruit and vegetables per day[@R46] and any diet where saturated fats account for less than 10% of the total daily energy intake.[@R47] In relation to physical activity, we will consider interventions that involve at least 150 or 75 minutes of moderate or vigorous aerobic exercise, respectively, per week, or an equivalent time where moderate and vigorous activities are combined.[@R49] Smoking cessation interventions will be required to include a self-reported and/or biochemically validated outcome of continuous abstinence, and/or prolonged abstinence, and/or point prevalence. In addition, we will include studies where treatment effect size is expressed as the absolute percentage difference between abstinence and smoking or the magnitude of the difference between active and control interventions. For continuous abstinence, any smoking between the quit day and the end of the follow-up will be considered a failure. Failure of prolonged abstinence will be defined as smoking seven consecutive days or at least once a week for two consecutive weeks after the quit day. Failure of point prevalence will be defined as any smoking 7 days prior to the follow-up.[@R50] Studies with pharmacological therapy for smoking cessation will be excluded.

Comparators {#s2e}
-----------

Comparator groups will include a usual care group, a waiting list group, a non-intervention group (patients undergo the same assessments as the treatment group, but were not engaged in any intervention) and attention controls (active control or placebo).

Outcome {#s2f}
-------

We will only include RCTs which primary or secondary outcome measure is variance in symptoms of depression. Outcomes must have been measured using validated rating scales for depression. If more than one scale was used to assess depression, only the results of the scale with the best psychometric properties for the setting and country will be used. If this information is not provided by the authors, a literature search will be conducted to find it out. When several scales have been used, the parameters used to select the best scale are: a higher Youden's J statistic (J=Sensitivity+Specificity−1), Cronbach's alpha and intraclass correlation coefficient (test--retest); and sensitivity to change over time (Yes/no/not available). Studies, where effects on depression and other mood disorders (eg, anxiety) are not provided separately, will be excluded.

Outcomes will have been addressed during the post-intervention period and the last follow-up visit of the study. When available, we will consider the average of all the follow-up visits.

Information resources and search strategy {#s2g}
-----------------------------------------

A literature search of the following electronic databases will be performed: MEDLINE (via Ovid and PubMed), Scopus, Cochrane Central Register of Controlled Trial, PsycINFO, Web of Science, OpenGrey Repository (System for Information on Grey Literature in Europe) and the International Clinical Trials Registry Platform. Additionally, an online [supplementary file](#SP1){ref-type="supplementary-material"} manual search will be performed using lists of references, references to expert authors and other systematic reviews and/or meta-analyses of multiple or single lifestyle interventions focused on healthy diet, physical activity or smoking cessation. The search strategy will involve the use of a set of terms selected from the relevant literature. We will use Medical Subject Headings and text words related to healthy diet, physical activity, smoking cessation and depression. The search will be first performed in MEDLINE and will subsequently be adapted to the other relevant databases. The time frame of the search will extend until the review is completed. The online [supplementary file](#SP1){ref-type="supplementary-material"} shows Medline's search strategy using the PICOS format in PubMed. No limits will be imposed on study language or publication date.
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Study selection {#s2h}
---------------

The study selection process will be performed in three phases: first, duplicated records will be eliminated; then a selection of titles and abstracts will be conducted; finally, only selected records will be read full-text. The whole process will be completed twice by two independent researchers. Discrepancies will be solved by consensus between the two reviewers; if the consensus is not reached, a third reviewer will make the final decision. The level of agreement between researches will be calculated using Kappa index.[@R51]

Data extraction {#s2i}
---------------

An evidence table will be generated to display the most relevant characteristics of each study. If several records of the same study are found, they will be computed as a single study, and data extraction will be made all at once using information from all the records. Paper screening and selection, and data extraction will be performed by two independent reviewers twice. Discrepancies will be solved by a third reviewer. In case of missing data, authors will be contacted. The following qualitative data will be collected: authors, year of publication, country, primary outcome, target population, target habits (healthy diet, physical activity and/or smoking cessation), characteristics of the complex intervention (total duration of the intervention, framework and session format), conditions, sample size (control/intervention), deliverer, outcome (measuring instrument), adherence to healthy habits at the end of the intervention and setting and duration of the follow-up.

Regarding quantitative data, we will extract means and SD, when available, to calculate the standardised mean difference (SMD). If some RCTs report other formats, Comprehensive Meta-analysis (CMA) will be used to obtain the equivalent SMD.

Risk of bias {#s2j}
------------

The internal validity of the selected studies will be assessed using the Cochrane Collaboration's tool for assessing risk of bias.[@R52] This tool assesses six general dimensions or criteria: selection bias (random sequence generation and allocation concealment), performance bias (blinding of participants and trial personnel), detection bias (blinding of evaluators of outcome assessment), attrition bias (missing outcome data), reporting bias (selective reporting) and other biases (other sources of bias). In all items, zero points are assigned for low risk of bias, one point for unclear risk and two points for high risk. The risk of bias will be assessed twice by two independent reviewers. Discrepancies will be solved by a third reviewer. The level of agreement between researches will be calculated using the intraclass correlation coefficient.[@R51] If additional information is required, authors will be contacted.

Assessment of publication bias {#s2k}
------------------------------

Publication bias will be assessed by a funnel plot. Duval and Tweedie's trim and fill procedure[@R53] will be used to impute missing data for the analysis. If the number of studies is equal or greater than 10, Begg and Mazumdar rank correlation[@R54] and Egger's test[@R55] will also be performed.

Statistical analysis {#s2l}
--------------------

Two independent reviewers will insert quantitative data from each study twice into an Excel sheet. If there are missing data that hinder effect size calculation, the authors will be contacted. If no response is received, the study will be excluded. We will use CMA to convert data into the desired format. Quantitative data will be analysed using CMA V.3 and STATA V.14. Effects size will be calculated using SMD and 95% CI. A negative SMD will be interpreted as a greater reduction of depressive symptoms in the intervention group. Cohen's interpretation will be used---that is, 0.20, 0.50 and 0.80 as small, medium and large effect size, respectively.[@R56] We selected a random-effects model for our meta-analysis, under the assumption that the RCTs to be included in our study will have been performed in heterogeneous populations that may differ from each other.

Heterogeneity will be assessed using forest plots, Q statistics, p values and I^2^ index values and their 95% CIs. I^2^ index values will be expressed as percentages and interpreted as follows: unimportant heterogeneity (0%--40%), moderate heterogeneity (30%--60%), substantial heterogeneity (50%--90%) and considerable heterogeneity (75%--100%).[@R38]

Sensitivity will be assessed during the first and last follow-up visit using fixed-effects model and Hedges' g. Some studies will be excluded from analysis (eg, studies with the highest risk of bias or causing the greatest increase in heterogeneity).

Sub-group analysis will be performed to explore heterogeneity across studies. When available, the following data will be collected: year of publication, country, primary outcome, target population, target habits (healthy diet and physical activity; healthy diet and smoking cessation; physical activity, smoking cessation and healthy diet; and physical activity and smoking cessation), severity of depressive symptoms at baseline, population age range, comparator (usual care, waiting list, non-intervention and attention controls), sample size, setting (ie, hospital, community hubs, school and workplace), characteristics of the complex intervention (total duration of the intervention, framework and session format), follow-up (short-term vs long- term), deliverer, and risk of bias.

Random-effects meta-regression will be used to identify differences in effect sizes in relation to risk of bias or time. Normality of distribution will be previously assessed by the Skewness and Kurtosis normality test.[@R57] When appropriate, quantitative variables will be transformed to improve approximation to normality. Covariables with p values less than 0.15, which were not previously removed from the model due to collinearity, will be included in meta-regression models. CIs and standard errors will be calculated by the Knapp and Hartung method.[@R58] We will also use Higgins and Thompson permutation test to calculate p values, taking multiplicity adjustment into account.[@R59] We will use a plot of standardised shrunken residuals to test goodness of fit in meta-regression models.

Quality of evidence {#s2m}
-------------------

Quality of evidence will be assessed using Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. GRADE system helps to determine if the estimated effect size is reliable or not as defined according to four categories: high, moderate, low and very low.[@R60]

Patient and public involvement {#s2n}
------------------------------

No patients or public involved.

Ethics and dissemination {#s3}
========================

This systematic review and meta-analysis study will be published in a peer-reviewed journal. Results will be presented in relevant international conferences. Due to the characteristics of this study, no ethical approval is required.

Discussion {#s4}
==========

To the best of our knowledge, this will be the first systematic review and meta-analysis to assess the effectiveness of complex multiple-risk lifestyle interventions (healthy diet, physical activity and/or smoking cessation) in reducing depressive symptoms in the adult population. In this study, we will summarise and evaluate the quality of the most relevant studies. Finally, we will provide an overview of the current body of knowledge on complex multiple-risk lifestyle interventions for reducing symptoms of depression. A meta-analysis will be performed and statistical integration of results will be used to compute common effect size and significance. The effect size, robustness and quality of evidence obtained in this meta-analysis will help to determine whether symptoms of depression can be reduced by complex multiple-risk lifestyle interventions based on the acquisition of healthy habits. The implication of the results obtained in this study is that complex multiple-risk lifestyle interventions could be routinely implemented in all patients at risk for depression in a variety of settings (ie, primary care centres, workplace, to name a few) and incorporated into treatment and prevention guidelines.
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